Daily Newsletter

16 August 2023

Share with colleague
Subscribe

Daily Newsletter

16 August 2023

Share with colleague
Subscribe

Spotlight

FDA approves Delcath’s liver-directed therapy for metastatic uveal melanoma

The Hepzato Kit delivers melphalan chemotherapy directly to the liver and will launch in Q4 2023.

Latest news

Gilead and Tentarix partner on cancer and inflammation therapies

Tentarix will obtain $66m in total from Gilead as upfront payments and equity investment under the three collaborations.

16 August 2023

Precision and Imugene conclude transaction for cancer drug azer-cel

Precision can earn $198m in extra milestone payments, along with double-digit royalties based on net sales.

16 August 2023

Avidity gains FDA orphan drug designation for DMD therapy

The Phase 1/2 EXPLORE44 study is currently assessing AOC 1044 as a treatment for individuals with DMD44.

16 August 2023

AGC and Asahi partner for clinical drug production in Seattle

AGC Biologics runs multiple mammalian cGMP manufacturing lines at the Seattle facility.

16 August 2023

Generative AI has the potential to revolutionise drug discovery

Examples of companies with generative AI platforms for drug discovery include Insilico Medicine, Exscientia, Iktos, Adaptyv Bio, and Absci.

16 August 2023

The NASH market holds untapped potential

The prevalence of nonalcoholic steatohepatitis (NASH), a more advanced stage of nonalcoholic fatty liver disease (NAFLD), with no FDA-approved therapies, continues to increase.

16 August 2023

Digital transformation of the healthcare industry is driving the demand and development for precision and personalized medicine

Per GlobalData estimates, the precision and personalized medicine market is expected to achieve a CAGR of more than 43% between 2022 and 2029. The digital transformation of the healthcare industry is driving the market demand. For example, advances in biomarker testing with NGS are improving patient selection, use of AI in identifying trends in big datasets is accelerating the time from drug discovery to commercialization, and the use of Industry 4.0 technologies is improving the quality and efficiency of manufacturing complex drugs such as cell and gene therapies.